Alcoholic liver disease progresses through three stages: fatty liver, alcoholic hepatitis, and cirrhosis. The first two stages are potentially reversible if you stop drinking. Cirrhosis is permanent, but stopping drinking at any stage slows progression, reduces complications, and significantly improves survival. The liver has a greater capacity to recover than most people realise, but only if the alcohol stops. Early-stage disease often has no symptoms, which is why many people do not realise they have it until significant damage has occurred.
Dr. Ponlawat Pitsuwan, physician and addiction medicine specialist at Phuket Island Rehab: “The most important thing I want patients with alcoholic liver disease to understand is that stopping drinking is not just one part of the treatment. It is the treatment. Every other intervention, nutritional support, medications, monitoring, works much better when alcohol stops. I have seen patients with significant liver damage achieve remarkable recovery once they stopped drinking and got proper support. The liver is a resilient organ. What it cannot do is recover while the insult continues.”
Can Alcoholic Liver Disease Be Reversed?
This is the question most people ask first, and the honest answer depends on which stage the disease has reached. The liver is one of the few organs in the body with a genuine capacity to regenerate damaged tissue. In alcoholic liver disease, that capacity is real but it has limits.
| Stage | What is happening | Is it reversible? | Recovery timeline with abstinence |
| Fatty liver (steatosis) | Fat accumulates inside liver cells; no scarring yet | Yes, fully reversible | 2 to 6 weeks of abstinence in most cases |
| Alcoholic hepatitis (mild to moderate) | Liver cells are inflamed and dying; early scarring may be present | Largely reversible with abstinence and treatment | Significant improvement within 3 months; full recovery possible over 6 to 12 months |
| Alcoholic hepatitis (severe) | Widespread liver cell death; acute-on-chronic liver failure possible | Partially reversible; some patients require transplant | Weeks to months with intensive treatment; survival depends on severity scores |
| Cirrhosis (compensated) | Extensive permanent scarring; liver still functioning adequately | Scarring does not reverse, but function can stabilise and improve | Portal hypertension and liver function can improve meaningfully over 1 to 5 years of abstinence |
| Cirrhosis (decompensated) | Liver failing; ascites, bleeding, encephalopathy present | Not reversible without transplant in many cases | Abstinence can stabilise and sometimes partially improve function; transplant may be needed |
Key point: Even with cirrhosis, stopping drinking significantly reduces the risk of further complications and improves survival. The five-year survival rate for people with cirrhosis who stop drinking is roughly double that of those who continue.
What Is Alcoholic Liver Disease?
Alcoholic liver disease (ALD) is the collective name for a range of liver conditions caused by prolonged heavy alcohol use. The liver is the organ primarily responsible for processing alcohol. When it has to deal with more alcohol than it can safely handle, over months and years, it sustains progressive damage.
The disease moves through stages, from the mildest and most reversible form (fatty liver) to the most serious (cirrhosis). In between lies alcoholic hepatitis, which can range from a mild, manageable condition to a life-threatening emergency. Many people move through these stages without knowing it because early liver disease rarely causes symptoms.
Alcoholic liver disease accounts for approximately 5.9% of all deaths globally and is one of the leading causes of chronic liver disease worldwide. (Source: World Health Organisation )
The Three Stages of Alcoholic Liver Disease
Stage 1: Fatty liver (alcoholic steatosis)
Fatty liver is the earliest and most common form of alcoholic liver disease. It occurs in up to 90 percent of people who drink heavily. When the liver processes alcohol, it produces fatty acids as a byproduct. These accumulate inside liver cells, causing them to swell. At this stage, the liver is enlarged but not yet scarred.
Fatty liver almost never causes noticeable symptoms. You might feel some heaviness or mild discomfort in the upper right abdomen, but most people feel nothing. Blood tests may show mildly elevated liver enzymes. The key clinical fact is this: if you stop drinking at this stage, the fat clears from the liver within two to six weeks and the liver returns to normal. No permanent damage has occurred.
Stage 2: Alcoholic hepatitis
Alcoholic hepatitis is liver inflammation caused by continued alcohol use after early damage has occurred. It can develop suddenly, sometimes in someone who has been drinking heavily for years without obvious symptoms. It can also develop gradually alongside worsening fatty liver.
Symptoms include jaundice (yellowing of the skin and whites of the eyes), abdominal pain and swelling, nausea and vomiting, fever, and severe fatigue. Mild alcoholic hepatitis can resolve with abstinence and nutritional support. Severe alcoholic hepatitis is a medical emergency with significant short-term mortality.
Severity is assessed using clinical scoring tools. The most widely used is the Maddrey Discriminant Function (MDF). An MDF score of 32 or above indicates severe disease and guides the decision to use corticosteroids. The Glasgow Alcoholic Hepatitis Score (GAHS) provides additional guidance on who is likely to benefit from treatment. If corticosteroids are started, a tool called the Lille Score is calculated at day 7 of treatment: a Lille Score above 0.45 indicates the treatment is not working and should be stopped.
Warning: Severe alcoholic hepatitis can progress to acute-on-chronic liver failure (ACLF), where multiple organ systems fail in rapid succession. ACLF has high short-term mortality and requires urgent hospital admission. If someone with known liver disease develops sudden severe jaundice, confusion, significant abdominal swelling, or difficulty breathing, seek emergency care immediately.
Stage 3: Cirrhosis
Cirrhosis is the result of years of ongoing liver damage. The liver attempts to repair itself by forming scar tissue, but this scar tissue (fibrosis) disrupts the liver’s normal architecture. Blood cannot flow through the liver properly, and the healthy liver cells that remain cannot keep up with the liver’s many functions.
Cirrhosis itself is permanent. Scar tissue does not dissolve. However, stopping drinking at this stage still matters enormously: it stops more scarring from forming, reduces the pressure that has built up in the blood vessels around the liver (portal hypertension), and improves the function of the healthy liver cells that remain. The liver can partially compensate and adapt, and people who stop drinking with cirrhosis live significantly longer than those who continue.
Cirrhosis is classified as compensated (the liver is damaged but still managing its functions) or decompensated (the liver is failing, producing serious complications). Once decompensation occurs, the priority becomes managing complications and assessing suitability for transplantation.
How Alcohol Damages the Liver: The Mechanisms
Understanding why alcohol is specifically toxic to the liver helps explain why the disease progresses the way it does.
Acetaldehyde and direct cell damage
When the liver processes alcohol, it converts it first into a toxic compound called acetaldehyde, using an enzyme called alcohol dehydrogenase (ADH). Acetaldehyde is highly reactive: it attaches to proteins and DNA inside liver cells and disrupts how those cells function and replicate. A second enzyme, aldehyde dehydrogenase (ALDH2), converts acetaldehyde into the harmless compound acetate. When alcohol consumption exceeds the liver’s processing capacity, acetaldehyde accumulates faster than ALDH2 can clear it.
Oxidative stress from CYP2E1
At higher alcohol concentrations, a second pathway takes over: the CYP2E1 enzyme. This enzyme processes alcohol but generates reactive oxygen species (ROS), which are unstable molecules that damage liver cell membranes, proteins, and DNA. With chronic heavy drinking, CYP2E1 activity is increased, meaning the liver produces more of these damaging molecules per unit of alcohol consumed over time. This is one reason why liver damage in heavy drinkers tends to accelerate rather than progress linearly.
Gut permeability and inflammation
Chronic heavy drinking increases the permeability of the gut lining, allowing bacterial fragments, particularly a molecule called lipopolysaccharide (LPS), to pass from the intestines into the portal blood supply that feeds the liver. LPS activates immune cells in the liver called Kupffer cells through a receptor called TLR4. Activated Kupffer cells release inflammatory signalling molecules including TNF-alpha, IL-1, and IL-6. This inflammatory cascade accelerates liver cell death and promotes scar tissue formation.
Stellate cell activation and fibrosis
The liver’s response to ongoing injury is to try to repair itself by activating cells called hepatic stellate cells. When activated, these cells produce collagen and other proteins that form scar tissue. In short-term injury this is protective. In chronic injury from sustained alcohol use, stellate cell activation becomes persistent, producing more and more collagen. The accumulated scar tissue disrupts blood flow through the liver and replaces functional liver tissue, which is the process of fibrosis progressing to cirrhosis.
Why women are more vulnerable
Women develop alcoholic liver disease at lower alcohol doses and after shorter periods of drinking than men. Two specific biological mechanisms explain this. First, women have lower levels of gastric alcohol dehydrogenase, the enzyme in the stomach that begins breaking down alcohol before it is absorbed. This means less alcohol is processed in the stomach and more reaches the bloodstream, producing higher blood alcohol concentrations from the same intake. Second, women generally have lower total body water, so alcohol becomes more concentrated in the blood. The combination means the liver of a woman who drinks the same amount as a man is exposed to higher effective alcohol concentrations.
Zinc depletion
Alcohol specifically impairs zinc absorption from the gut and increases zinc excretion through the kidneys. Zinc is a cofactor for more than 300 enzymes, including alcohol dehydrogenase itself. When zinc is depleted, ADH function is impaired and the liver’s general capacity to process alcohol and repair itself is reduced. Zinc supplementation has shown measurable benefit in reducing liver inflammation markers in ALD, which is why it is included in nutritional protocols alongside thiamine and other B vitamins.
Symptoms and Diagnosis
Symptoms by stage
| Stage | Common symptoms | When to seek help |
| Fatty liver | Usually none; mild right upper abdominal heaviness in some | If you drink heavily, request liver enzyme blood tests at your next GP visit |
| Mild to moderate alcoholic hepatitis | Fatigue, nausea, mild jaundice, reduced appetite, abdominal discomfort | Within days: do not wait to see if symptoms pass |
| Severe alcoholic hepatitis | Pronounced jaundice, fever, significant abdominal swelling, confusion | Emergency: go to hospital immediately |
| Compensated cirrhosis | Fatigue, mild jaundice, spider veins on skin, enlarged abdomen, muscle wasting | Urgent: requires specialist assessment and monitoring |
| Decompensated cirrhosis | Large fluid-filled abdomen (ascites), leg swelling, confusion, vomiting blood, dark tarry stools | Emergency: hospital admission required |
How it is diagnosed
No single test confirms alcoholic liver disease. Diagnosis combines drinking history, physical examination, blood tests, and imaging. Blood tests typically show elevated liver enzymes, with AST (aspartate aminotransferase) usually higher than ALT (alanine aminotransferase), often with an AST to ALT ratio greater than 2:1. This pattern is characteristic of alcohol-related liver injury rather than other causes. Bilirubin, albumin, and INR (a clotting measure) are checked to assess liver function. A low albumin and raised INR indicate more advanced disease.
Ultrasound is usually the first imaging used. It can detect a fatty, enlarged liver, assess for cirrhosis changes, and identify ascites or liver masses. More detailed imaging with CT or MRI is used when needed. A liver biopsy, where a small tissue sample is taken with a needle, is not always necessary but provides the most accurate picture of inflammation and fibrosis severity when the diagnosis is uncertain.
The MELD score (Model for End-stage Liver Disease) is a numerical calculation based on bilirubin, INR, and creatinine that estimates 90-day mortality risk. It is used to prioritise patients for liver transplantation and to guide treatment intensity.
Serious Complications of Advanced Disease
Once cirrhosis develops, the liver’s disrupted structure creates a cascade of potential complications. Understanding these helps explain why advanced ALD is managed as a complex, multi-system condition rather than just a liver problem.
Portal hypertension occurs when scar tissue impedes blood flow through the liver, causing pressure to build in the portal vein. This pushes blood into alternative vessels that were not designed to carry high-pressure flow, particularly in the oesophagus and stomach (varices). These varices can rupture, causing severe internal bleeding that is a medical emergency. Beta-blocker medications and endoscopic banding procedures are used to reduce this risk. The hepatic venous pressure gradient (HVPG), measured via a specialised catheter procedure, is the gold standard for assessing how severe portal hypertension is.
Ascites is fluid accumulation in the abdominal cavity caused by portal hypertension and reduced albumin production. It causes abdominal distension, discomfort, and reduced mobility. Ascites can become infected (spontaneous bacterial peritonitis), which is a life-threatening complication requiring immediate antibiotic treatment. Management involves low-sodium diet, diuretics, and in severe cases regular drainage (paracentesis).
Hepatic encephalopathy develops when the failing liver cannot clear toxins, particularly ammonia, from the blood. These toxins affect brain function, causing confusion, personality changes, sleep disturbance, and in severe cases coma. Lactulose and rifaximin are the main treatments. Hepatorenal syndrome is kidney failure that develops as a consequence of severe liver disease, even when the kidneys themselves are structurally normal, caused by circulatory changes driven by portal hypertension.
Hepatocellular carcinoma (liver cancer) risk increases substantially once cirrhosis is established. Six-monthly ultrasound surveillance is recommended for cirrhotic patients for this reason.
Treatment
Stopping drinking: the single most effective intervention
Every other treatment for alcoholic liver disease works better when drinking stops. In fatty liver, abstinence alone is curative. In alcoholic hepatitis, abstinence combined with nutritional support produces the best outcomes. In cirrhosis, abstinence prevents further progression and significantly improves survival. No medication currently available produces results that come close to what abstinence achieves in this disease.
Medically supervised detoxification is essential for anyone with significant alcohol dependence, because withdrawal from alcohol can cause seizures and delirium tremens (DTs), particularly dangerous in someone with compromised liver function. Benzodiazepines are used to manage withdrawal safely under medical supervision.
Nutritional support
Malnutrition is almost universal in significant alcoholic liver disease. Alcohol displaces food and directly impairs the absorption of multiple nutrients. Thiamine (vitamin B1) deficiency is common and can cause Wernicke’s encephalopathy, a serious neurological emergency. Thiamine is given before glucose in acutely ill patients for this reason. Zinc deficiency impairs liver enzyme function and wound healing. Vitamins A, D, E, K, folate, and B12 are commonly depleted. Protein intake of 1.2 to 1.5 grams per kilogram of body weight daily is recommended to prevent muscle wasting (sarcopenia), which worsens outcomes in cirrhosis.
Pharmacological treatment for severe alcoholic hepatitis
Prednisolone (a corticosteroid, not to be confused with prednisone, which requires hepatic conversion and is less suitable in liver disease) is the only currently established pharmacological treatment for severe alcoholic hepatitis, defined by an MDF score of 32 or above. The landmark STOPAH trial published in 2015 showed that prednisolone significantly reduced 28-day mortality in severe alcoholic hepatitis, though the survival benefit was not significant at 90 days or one year. This means prednisolone buys time and reduces early deaths, but does not fundamentally alter the long-term course without sustained abstinence.
The Lille Score at day 7 of prednisolone treatment determines whether to continue. A score above 0.45 indicates the patient is not responding to corticosteroids and treatment is stopped, as continuing provides no benefit and increases infection risk. N-acetylcysteine is used as an adjunct to prednisolone in some centres based on trial evidence suggesting it further reduces 30-day mortality, though it is not universally adopted as standard of care.
Pentoxifylline, previously used as an alternative to prednisolone, was shown by the STOPAH trial to have no significant survival benefit. It is no longer recommended in most guidelines.
Emerging therapy: Faecal microbiota transplantation (FMT), which involves transferring gut bacteria from a healthy donor, has shown early promising results in clinical trials for severe alcoholic hepatitis. It targets the gut-liver axis: restoring a healthier gut microbiome reduces the LPS-mediated inflammatory activation of Kupffer cells. FMT is not yet standard care but represents one of the most actively researched new approaches in this field.
Medications to support abstinence in liver disease
Managing alcohol use disorder alongside liver disease requires care in medication selection. Disulfiram (Antabuse) is relatively contraindicated in patients with significant liver disease because it can itself cause hepatotoxicity. Naltrexone requires caution and monitoring in liver disease but can be used at lower doses in patients with less severe impairment. Acamprosate is cleared by the kidneys rather than the liver, making it the pharmacologically safest option in patients with significant hepatic impairment. Baclofen, a GABA-B receptor agonist not formally licensed for AUD in most countries but used off-label, has been specifically studied in patients with cirrhosis and AUD, where other AUD medications carry more risk. Some hepatology centres use it specifically in this population based on that evidence.
Clinical insight: Dr. Ponlawat Pitsuwan: “The medication question in alcoholic liver disease is one where generalising from the standard AUD treatment literature can be dangerous. Disulfiram, which some clinicians still reach for, is genuinely problematic in liver disease. Acamprosate is often the safest starting point. Baclofen is worth knowing about for patients with cirrhosis where other options are limited. Getting the AUD treatment right is just as important as managing the liver complications, because without sustained abstinence, the rest is just managing decline.”
Liver transplantation
Liver transplantation is the only treatment that can restore liver function once end-stage disease develops. Survival rates after transplantation for ALD now reach 80 to 85 percent at one year, comparable to transplantation for other liver diseases. The traditional requirement for six months of abstinence before transplantation has been increasingly questioned and many centres now consider early transplantation for severe alcoholic hepatitis that does not respond to medical therapy, with selection based on multidisciplinary psychosocial assessment rather than a fixed abstinence period. Long-term outcomes depend heavily on maintained abstinence after transplantation.
The British Society of Gastroenterology guidelines on the management of alcohol-related liver disease provide the most current UK clinical guidance on diagnosis, scoring, treatment, and transplantation criteria. (Source: British Society of Gastroenterology )
Addressing the Alcohol Use Disorder Alongside the Liver Disease
Alcoholic liver disease does not exist independently of alcohol use disorder. Treating the liver without addressing the drinking is like treating a wound that is being continually reopened. The two conditions require simultaneous attention, and the best outcomes in ALD come from integrated care that addresses both.
People with ALD frequently have coexisting depression, anxiety, and social difficulties that contributed to heavy drinking and that make abstinence harder to maintain without support. A liver diagnosis is often a moment of genuine motivation for change: people who might not have engaged with addiction treatment before become ready to engage when the physical reality of liver damage is concrete and visible. This is a clinical opportunity that should not be missed.
Support: Phuket Island Rehab provides integrated support for people with alcohol use disorder and its medical consequences, including liver disease. If you or someone you care about has been told their liver is affected by drinking and they want help stopping, please reach out. In the US, call or text 988 at any time. Text HOME to 741741 on the Crisis Text Line. International support is available at befrienders.org.
Summary
Alcoholic liver disease progresses through three stages: fatty liver, which is fully reversible with abstinence; alcoholic hepatitis, which ranges from manageable to life-threatening and is largely reversible in milder forms; and cirrhosis, which is permanent but can be stabilised and partially compensated for by stopping drinking. The liver has genuine regenerative capacity in the earlier stages, and even with cirrhosis, abstinence produces significantly better outcomes than continued drinking.
The disease is driven by multiple mechanisms: acetaldehyde toxicity from alcohol metabolism, oxidative stress from CYP2E1 activation, inflammatory cascade triggered by gut-derived bacterial fragments activating Kupffer cells via TLR4, and progressive fibrosis from stellate cell activation. Women are more vulnerable at lower alcohol doses due to reduced gastric first-pass metabolism and lower body water. Zinc depletion is a specific and underappreciated mechanism that impairs the liver’s own processing capacity.
Treatment for severe alcoholic hepatitis is guided by the Maddrey Discriminant Function, the Glasgow Alcoholic Hepatitis Score, and the Lille Score at day 7 of prednisolone therapy. The STOPAH trial established prednisolone’s short-term benefit and pentoxifylline’s lack of benefit. Faecal microbiota transplantation is an emerging therapy with early trial evidence. AUD medication selection in liver disease requires specific attention: acamprosate is safest in hepatic impairment, baclofen has specific evidence in cirrhotic patients, and disulfiram should be avoided.
As Dr. Ponlawat Pitsuwan of Phuket Island Rehab puts it: “The liver can do remarkable things when given the chance. What it cannot do is recover while the alcohol continues. Stopping drinking is not the beginning of treatment for alcoholic liver disease. It is the treatment. Everything else supports and supplements that central fact.”
Frequently Asked Questions
How much do you have to drink to get alcoholic liver disease?
Fatty liver can develop after just a few weeks of heavy drinking. Clinically, heavy drinking is defined as more than 14 units per week for women or 21 units per week for men on a sustained basis, though these are population thresholds and individual susceptibility varies significantly. Women develop liver disease at lower intake levels than men due to differences in how their bodies process alcohol. Duration matters as much as volume: drinking heavily for ten years carries substantially more risk than drinking the same amount for two years. Some people develop significant liver disease at lower consumption levels due to genetic factors, coexisting conditions like hepatitis C, or obesity.
What are the first signs of alcoholic liver disease?
Fatty liver, the most common first stage, typically causes no symptoms at all. The first signs that something is wrong often appear only when the disease has progressed to alcoholic hepatitis: fatigue that does not improve with rest, loss of appetite, mild yellowing of the skin or eyes, discomfort in the upper right abdomen, and nausea. Because early disease is symptom-free, people who drink heavily should request liver enzyme blood tests during routine health checks rather than waiting for symptoms to appear.
Can the liver recover from alcoholic liver disease?
Yes, but it depends on the stage. Fatty liver recovers completely within two to six weeks of stopping drinking. Mild to moderate alcoholic hepatitis largely resolves with abstinence and nutritional support, with significant improvement over three to twelve months. Cirrhosis does not reverse, but its complications can be reduced and its progression can be halted by stopping drinking. The earlier abstinence begins, the more recovery is possible. Even people who have developed cirrhosis live significantly longer if they stop drinking.
Is alcoholic liver disease the same as cirrhosis?
No. Cirrhosis is one stage of alcoholic liver disease, the most advanced one. Alcoholic liver disease is the broader term covering all three stages: fatty liver, alcoholic hepatitis, and cirrhosis. Many people with alcoholic liver disease have fatty liver or hepatitis and have not yet developed cirrhosis. Receiving a diagnosis of alcoholic liver disease does not automatically mean you have cirrhosis, though without abstinence the disease can progress to that stage.
What is the treatment for severe alcoholic hepatitis?
Severe alcoholic hepatitis is defined by a Maddrey Discriminant Function score of 32 or above. Treatment involves hospital admission, nutritional support, abstinence from alcohol, and prednisolone (a corticosteroid). If prednisolone is started, a Lille Score is calculated at day 7 to check whether it is working. A score above 0.45 means treatment is stopped. N-acetylcysteine is used alongside prednisolone in some centres. Liver transplantation may be considered in cases that do not respond to medical treatment, with careful psychosocial evaluation rather than a fixed abstinence period determining eligibility.
Can you get a liver transplant for alcoholic liver disease?
Yes. Liver transplantation is now a well-established treatment for end-stage alcoholic liver disease, with survival rates of 80 to 85 percent at one year. The traditional requirement for six months of abstinence before listing is no longer considered the only determining factor at many transplant centres. Patients are evaluated by a multidisciplinary team that considers psychosocial factors, support systems, insight into the illness, and overall medical fitness rather than abstinence duration alone. Early transplantation for severe alcoholic hepatitis that does not respond to medical treatment is a growing practice with encouraging outcomes.